|

Mosunetuzumab Clinical Trials

24 actively recruiting trials across 17 locations

Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A +7 more

Pipeline

Phase 1: 3Phase 2: 14Phase 3: 2Phase 1/2: 4

Top Sponsors

  • University of Washington2
  • M.D. Anderson Cancer Center2
  • City of Hope Medical Center2
  • Weill Medical College of Cornell University1
  • Washington University School of Medicine1

Indications

  • Cancer24
  • B Cell Lymphoma4
  • Follicular Lymphoma4
  • Diffuse Large B-Cell Lymphoma3
  • Lymphoma3

Other3 trials

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Phase 2
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

Phoenix, Arizona2 trials

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Mayo Clinic in Arizona - Phoenix

Phase 1/2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Duarte, California2 trials

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

City of Hope Medical Center

Phase 2

Houston, Texas2 trials

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

MD Anderson Cancer Center

Phase 2
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M D Anderson Cancer Center

Phase 2

Seattle, Washington2 trials

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama1 trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

University of Alabama at Birmingham Cancer Center

Phase 3

Tucson, Arizona1 trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Clovis, California1 trial

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

University of California San Francisco - Fresno Center for Medical Education and Research

Phase 1

New Haven, Connecticut1 trial

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Yale Cancer Center

Phase 2

Washington D.C., District of Columbia1 trial

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Georgetown University (Data Collection Only)

Phase 2

Miami, Florida1 trial

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

University of Miami

Phase 2

Boston, Massachusetts1 trial

Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital

Phase 1/2

Rochester, Minnesota1 trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Mayo Clinic Rochester

Phase 1

St Louis, Missouri1 trial

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Washington University School of Medicine

Phase 1

Omaha, Nebraska1 trial

CAR-T Followed by Bispecific Antibodies

University of Nebraska Medical Center

Phase 2

New York, New York1 trial

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Weill Cornell Medicine/NewYork-Presbyterian Hospital

Phase 2

Rochester, New York1 trial

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Wilmot Cancer Institute

Phase 2

Portland, Oregon1 trial

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

OHSU Knight Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.